Genetics of ischemic stroke, stroke-related risk factors, stroke precursors and treatments

Pharmacogenomics

Volumn 13, Issue 5, 2012, Pages 595-613

  Della Morte, David ^a,b   Guadagni, Fiorella ^b   Palmirotta, Raffaele ^b   Testa, Gianluca ^c,d   Caso, Valeria ^e   Paciaroni, Maurizio ^e   Abete, Pasquale ^c   Rengo, Franco ^c   Ferroni, Patrizia ^b   Sacco, Ralph L ^a   Rundek, Tatjana ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF MOLISE   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

Author keywords

atherosclerosis; carotid intima media thickness; carotid plaque; genes; genome wide association study; ischemic stroke; monogenic stroke; pharmacogenetics; SNPs; vascular risk factors

Indexed keywords

CLOPIDOGREL; PLACEBO; PRASUGREL; TICAGRELOR; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; BRAIN ISCHEMIA; CADASIL; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; FABRY DISEASE; FOOD DRUG INTERACTION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEREDITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LACTIC ACIDOSIS; LEUKOENCEPHALOPATHY; LIFESTYLE; MITOCHONDRIAL ENCEPHALOMYOPATHY; MONOGENIC DISORDER; MOYAMOYA DISEASE; ONSET AGE; PATHOGENESIS; PHARMACOGENETICS; PHENOTYPE; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; WHITE MATTER;

ANTICOAGULANTS; BRAIN ISCHEMIA; CAROTID STENOSIS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; RISK FACTORS; STROKE; THIENOPYRIDINES; TUNICA INTIMA; WARFARIN;

EID: 84859222074     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.14     Document Type: Review

References (155)

1. Herrera VL, Ruiz-Opazo N. Genetic studies in rat models: insights into cardiovascular disease. Curr. Opin. Lipidol. 16(2), 179-191 (2005). (Pubitemid 40515892)
2. Flossmann E, Schulz UG, Rothwell PM. Systematic review of methods and results of studies of the genetic epidemiology of ischemic stroke. Stroke 35(1), 212-227 (2004). (Pubitemid 38057622)
3. Guo JM, Liu AJ, Su DF. Genetics of stroke. Acta Pharmacol. Sin. 31(9), 1055-1064 (2010).
4. Schulz UG, Flossmann E, Rothwell PM. Heritability of ischemic stroke in relation to age, vascular risk factors, and subtypes of incident stroke in population-based studies. Stroke 35(4), 819-824 (2004). (Pubitemid 38419784)
5. Jerrard-Dunne P, Cloud G, Hassan A, Markus HS. Evaluating the genetic component of ischemic stroke subtypes: a family history study. Stroke 34(6), 1364-1369 (2003). (Pubitemid 36693499)
6. Matarin M, Singleton A, Hardy J, Meschia J. The genetics of ischaemic stroke. J. Intern. Med. 267(2), 139-155 (2010).
7. Gretarsdottir S, Thorleifsson G, Reynisdottir ST et al. The gene encoding phosphodiesterase 4D confers risk of ischemic stroke. Nat. Genet. 35(2), 131-138 (2003). (Pubitemid 37187631)
8. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. 36(3), 233-239 (2004). (Pubitemid 38282747)
9. Rosand J, Bayley N, Rost N, de Bakker PI. Many hypotheses but no replication for the association between PDE4D and stroke. Nat. Genet. 38(10), 1091-1092 (2006). (Pubitemid 44470348)
10. Kostulas K, Gretarsdottir S, Kostulas V et al. PDE4D and ALOX5AP genetic variants and risk for ischemic cerebrovascular disease in Sweden. J. Neurol. Sci. 263(1-2), 113-117 (2007). (Pubitemid 350029850)
11. Matarin M, Brown WM, Dena H et al. Candidate gene polymorphisms for ischemic stroke. Stroke 40(11), 3436-3442 (2009).
12. Matarin M, Brown WM, Scholz S et al. A genome-wide genotyping study in patients with ischaemic stroke: initial analysis and data release. Lancet Neurol. 6(5), 414-420 (2007). (Pubitemid 46551853)
13. Ikram MA, Seshadri S, Bis JC et al. Genomewide association studies of stroke. N. Engl. J. Med. 360(17), 1718-1728 (2009).
14. Arnett DK, Baird AE, Barkley RA et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 115(22), 2878-2901 (2007). (Pubitemid 46869676)
15. Lorenz MW, Bickel H, Bots ML et al.; PROG-IMT Study Group. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG-IMT): rationale and design of a meta-analysis project. Am. Heart J. 159(5), 730-736.e2 (2010).
16. Rundek T, Arif H, Boden-Albala B et al. Carotid plaque, a subclinical precursor of vascular events: the Northern Manhattan Study. Neurology 70(14), 1200-1207 (2008). (Pubitemid 351482586)
17. Juo SH. Genetics of carotid atherosclerosis. Front. Biosci. 14, 4525-4534 (2009).
18. Andre C. CADASIL: pathogenesis, clinical and radiological findings and treatment. Arq. Neuropsiquiatr. 68(2), 287-299 (2010).
19. Joutel A, Corpechot C, Ducros A et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 383(6602), 707-710 (1996). (Pubitemid 26360644)
20. Razvi SS, Davidson R, Bone I, Muir KW. The prevalence of cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) in the west of Scotland. J. Neurol. Neurosurg. Psychiatry 76(5), 739-741 (2005). (Pubitemid 40569692)
21. Francis J, Raghunathan S, Khanna P. The role of genetics in stroke. Postgrad. Med. J. 83(983), 590-595 (2007). (Pubitemid 47425610)
22. Baird AE. Genetics and genomics of stroke: novel approaches. J. Am. Coll. Cardiol. 56(4), 245-253 (2010).
23. Dichgans M. Genetics of ischaemic stroke. Lancet Neurol. 6(2), 149-161 (2007). (Pubitemid 46097541)
24. Caplan LR, Arenillas J, Cramer SC et al. Stroke-related translational research. Arch. Neurol. 68(9), 1110-1123 (2011).
25. Mawet J, Vahedi K, Aout M et al. Carotid atherosclerotic markers in CADASIL. Cerebrovasc. Dis. 31(3), 246-252 (2011).
26. Fukutake T, Hirayama K. Familial youngadult- onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur. Neurol. 35(2), 69-79 (1995).
27. Hara K, Shiga A, Fukutake T et al. Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease. N. Engl. J. Med. 360(17), 1729-1739 (2009).
28. Deegan PB, Baehner AF, Barba Romero MA et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet. 43(4), 347-352 (2006).
29. Brady RO. Enzymatic abnormalities in diseases of sphingolipid metabolism. Clin. Chem. 13(7), 565-577 (1967).
30. Pastores GM, Lien YH. Biochemical and molecular genetic basis of Fabry disease. J. Am. Soc. Nephrol. 13(Suppl. 2), 130-133 (2002).
31. Ballabio E, Bersano A, Bresolin N, Candelise L. Monogenic vessel diseases related to ischemic stroke: a clinical approach. J. Cereb. Blood Flow Metab. 27(10), 1649-1662 (2007). (Pubitemid 47476103)
32. Steiger HJ, Hanggi D, Assmann B, Turowski B. Cerebral angiopathies as a cause of ischemic stroke in children: differential diagnosis and treatment options. Dtsch Arztebl. Int. 107(48), 851-856 (2010).
33. Smith ER, Scott RM. Moyamoya: epidemiology, presentation, and diagnosis. Neurosurg. Clin. N. Am. 21(3), 543-551 (2010).
34. Miskinyte S, Butler MG, Herve D et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am. J. Hum. Genet. 88(6), 718-728 (2011).
35. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H. Prediction of coronary heart disease using risk factor categories. Circulation 97(18), 1837-1847 (1998). (Pubitemid 28213628)
36. Keating MT, Sanguinetti MC. Molecular genetic insights into cardiovascular disease. Science 272(5262), 681-685 (1996). (Pubitemid 26000272)
37. Banerjee A, Silver LE, Heneghan C et al. Relative familial clustering of cerebral versus coronary ischemic events. Circ. Cardiovasc. Genet. 4(4), 390-396 (2011).
38. Zareba W, Moss AJ, Schwartz PJ et al. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N. Engl. J. Med. 339(14), 960-965 (1998). (Pubitemid 28455098)
39. Xu X, Rogus JJ, Terwedow HA et al. An extreme-sib-pair genome scan for genes regulating blood pressure. Am. J. Hum. Genet. 64(6), 1694-1701 (1999). (Pubitemid 30481522)
40. Chagnon YC, Perusse L, Weisnagel SJ, Rankinen T, Bouchard C. The human obesity gene map: the 1999 update. Obes. Res. 8(1), 89-117 (2000).
41. Almasy L, Hixson JE, Rainwater DL et al. Human pedigree-based quantitative-trait-locus mapping: localization of two genes influencing HDL-cholesterol metabolism. Am. J. Hum. Genet. 64(6), 1686-1693 (1999). (Pubitemid 30481521)
42. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285(18), 2370-2375 (2001). (Pubitemid 32424106)
43. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 110(9), 1042-1046 (2004). (Pubitemid 39319000)
44. Ellinor PT, Shin JT, Moore RK, Yoerger DM, MacRae CA. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 107(23), 2880-2883 (2003). (Pubitemid 36736626)
45. Darbar D, Hardy A, Haines JL, Roden DM. Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. J. Am. Coll. Cardiol. 51, 1083-1089 (2008). (Pubitemid 351374770)
46. Ruan Y, Liu N, Priori SG. Sodium channel mutations and arrhythmias. Nat. Rev. Cardiol. 6(5), 337-348 (2009).
47. Watanabe H, Darbar D, Kaiser DW et al. Mutations in sodium channel beta1- and beta2-subunits associated with atrial fibrillation. Circ. Arrhythm. Electrophysiol. 2(3), 268-275 (2009).
48. Wang Q, Shen J, Splawski I et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 80(5), 805-811 (1995).
49. Makiyama T, Akao M, Shizuta S et al. A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. J. Am. Coll. Cardiol. 52(18), 1326-1334 (2008).
50. Li Q, Huang H, Liu G et al. Gain-of-function mutation of Nav1.5 in atrial fibrillation enhances cellular excitability and lowers the threshold for action potential firing. Biochem. Biophys. Res. Commun. 380(1), 132-137 (2009).
51. Ellinor PT, Nam EG, Shea MA, Milan DJ, Ruskin JN. Cardiac sodium channel mutation in atrial fibrillation. Heart Rhythm 5(1), 99-105 (2008).
52. Schwartz PJ, Priori SG, Locati EH et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 92(12), 3381-3386 (1995).
53. Donnan GA, Davis SM, Thrift A. The role of blood pressure lowering before and after stroke. Curr. Opin. Neurol. 16(1), 81-86 (2003). (Pubitemid 36206766)
54. Chen YH, Xu SJ, Bendahhou S et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 299(5604), 251-254 (2003). (Pubitemid 36125211)
55. Das S, Makino S, Melman YF et al. Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. Heart Rhythm 6(8), 1146-1153 (2009).
56. Olson TM, Alekseev AE, Liu XK et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum. Mol. Genet. 15(14), 2185-2191 (2006). (Pubitemid 43985509)
57. Yang T, Yang P, Roden DM, Darbar D. Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. Heart Rhythm 7(9), 1246-1252 (2010).
58. Hodgson-Zingman DM, Karst ML et al. Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. N. Engl. J. Med. 359(2), 158-165 (2008). (Pubitemid 351962039)
59. Gretarsdottir S, Thorleifsson G, Manolescu A et al. Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke. Ann. Neurol. 648(4), 402-409 (2008).
60. Schunkert H, Gotz A, Braund P et al. Repeated replication and a prospective meta-analysis of the association between chromosome 9p21.3 and coronary artery disease. Circulation 117(13), 1675-1684 (2008). (Pubitemid 351482592)
61. Gschwendtner A, Bevan S, Cole JW et al. Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann. Neurol. 65(5), 531-539 (2009).
62. Anderson CD, Biffi A, Rost NS, Cortellini L, Furie KL, Rosand J. Chromosome 9p21 in ischemic stroke: population structure and meta-analysis. Stroke 41(16), 1123-1131 (2010).
63. Helgadottir A, Thorleifsson G, Magnusson KP et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 40(2), 217-224 (2008). (Pubitemid 351171400)
64. Visel A, Zhu Y, May D et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 464(7287), 409-412 (2010).
65. Nicolaou M, DeStefano AL, Gavras I et al. Genetic predisposition to stroke in relatives of hypertensives. Stroke 31(2), 487-492 (2000). (Pubitemid 30078187)
66. Lifton RP, Dluhy RG, Powers M et al. A chimaeric 11 beta-hydroxylase/ aldosterone synthase gene causes glucocorticoidremediable aldosteronism and human hypertension. Nature 355(6357), 262-265 (1992).
67. Shimkets RA, Warnock DG, Bositis CM et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 79(3), 407-414 (1994). (Pubitemid 24346056)
68. Hansson JH, Nelson-Williams C, Suzuki H et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat. Genet. 11(1), 76-82 (1995).
69. Kristjansson K, Manolescu A, Kristinsson A et al. Linkage of essential hypertension to chromosome 18q. Hypertension 39(6), 1044-1049 (2002). (Pubitemid 34620121)
70. Bianchi G, Tripodi G, Casari G et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc. Natl Acad. Sci. USA 91(9), 3999-4003 (1994). (Pubitemid 24139560)
71. O'Donnell CJ, Lindpaintner K, Larson MG et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation 97(18), 1766-1772 (1998).
72. Hingorani AD, Jia H, Stevens PA et al. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J. Hypertens. 13(12), 1602-1609 (1995). (Pubitemid 26015783)
73. Ned RM, Yesupriya A, Imperatore G et al. The ACE I/D polymorphism in US adults: limited evidence of association with hypertension-related traits and sex-specific effects by race/ethnicity. Am J. Hypertens. 25(2), 209-215 (2011).
74. Ansell BJ. Cholesterol, stroke risk, and stroke prevention. Curr. Atheroscler. Rep. 2(2), 92-96 (2000).
75. Shoulders CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum. Mol. Genet. 13(1), 149-160 (2004).
76. Eichenbaum-Voline S, Olivier M et al. Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 24(1), 167-174 (2004). (Pubitemid 38082429)
77. Huertas-Vazquez A, del Rincon JP, Canizales- Quinteros S et al. Contribution of chromosome 1q21-q23 to familial combined hyperlipidemia in Mexican families. Ann. Hum. Genet. 68(5), 419-427 (2004). (Pubitemid 39405952)
78. Roses AD. Apolipoprotein E in neurology. Curr. Opin. Neurol. 9(4), 265-270 (1996). (Pubitemid 26273284)
79. Huang Y. Mechanisms linking apolipoprotein E isoforms with cardiovascular and neurological diseases. Curr. Opin. Lipidol. 21(4), 337-345 (2010).
80. Jeng JS, Sacco RL, Kargman DE et al. Apolipoproteins and carotid artery atherosclerosis in an elderly multiethnic population: the Northern Manhattan Stroke Study. Atherosclerosis 165(2), 317-325 (2002). (Pubitemid 35333358)
81. Dong C, Beecham A, Wang L et al. Genetic loci for blood lipid levels identified by linkage and association analyses in Caribbean Hispanics. J. Lipid Res. 52(7), 1411-1419 (2011).
82. Sacco RL. Reducing the risk of stroke in diabetes: what have we learned that is new? Diabetes Obes. Metab. 4(Suppl. 1), 27-34 (2002).
83. Awata T, Kurihara S, Kikuchi C et al. Evidence for association between the class I subset of the insulin gene minisatellite (IDDM2 locus) and IDDM in the Japanese population. Diabetes 46(10), 1637-1642 (1997). (Pubitemid 27411242)
84. Yamagata K, Oda N, Kaisaki PJ et al. Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384, 455-458 (1996). (Pubitemid 26414660)
85. Davies JL, Kawaguchi Y, Bennett ST et al. A genome-wide search for human Type 1 diabetes susceptibility genes. Nature 371(6608), 130-136 (1994). (Pubitemid 24284009)
86. Hashimoto L, Habita C, Beressi JP et al. Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome 11q. Nature 371(6493), 161-164 (1994). (Pubitemid 24284015)
87. Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of Type 2 diabetes. Nat. Genet. 38(3), 320-323 (2006).
88. Helgason A, Palsson S, Thorleifsson G et al. Refining the impact of TCF7L2 gene variants on Type 2 diabetes and adaptive evolution. Nat. Genet. 39(2), 218-225 (2007). (Pubitemid 46184353)
89. Bielinski SJ, Pankow JS, Folsom AR, North KE, Boerwinkle E. TCF7L2 single nucleotide polymorphisms, cardiovascular disease and all-cause mortality: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51(6), 968-970 (2008).
90. Meyer JS, Kawamura J, Terayama Y. White matter lesions in the elderly. J. Neurol. Sci. 110(1-2), 1-7 (1992).
91. Carmelli D, DeCarli C, Swan GE et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 29(6), 1177-1181 (1998). (Pubitemid 28265474)
92. Reed T, Kirkwood SC, DeCarli C et al. Relationship of family history scores for stroke and hypertension to quantitative measures of white-matter hyperintensities and stroke volume in elderly males. Neuroepidemiology 19(2), 76-86 (2000). (Pubitemid 30111736)
93. Atwood LD, Wolf PA, Heard-Costa NL et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 35(7), 1609-1613 (2004). (Pubitemid 38823634)
94. Turner ST, Fornage M, Jack CR Jr et al. Genomic susceptibility loci for brain atrophy, ventricular volume, and leukoaraiosis in hypertensive sibships. Arch. Neurol. 66(7), 847-857 (2009).
95. Johnsen SH, Mathiesen EB. Carotid plaque compared with intima-media thickness as a predictor of coronary and cerebrovascular disease. Curr. Cardiol. Rep. 11(1), 21-27 (2009).
96. O'Leary DH, Polak JF, Kronmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N. Engl. J. Med. 340(1), 14-22 (1999). (Pubitemid 29024679)
97. Spence JD. Measurement of intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies. Int. J. Stroke 1(4), 216-221 (2006).
98. Rundek T, Brook RD, Spence JD. Letter by Rundek et al. regarding article, Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 116(9), e317-e318 (2007).
99. Abe Y, Rundek T, Sciacca RR et al. Ultrasound assessment of subclinical cardiovascular disease in a community-based multiethnic population and comparison to the Framingham score. Am. J. Cardiol. 98(10), 1374-1378 (2006). (Pubitemid 44666648)
100. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74(6), 1399-1406 (1986). (Pubitemid 17189260)
101. Heiss G, Sharrett AR, Barnes R et al. Carotid atherosclerosis measured by B-mode ultrasound in populations: associations with cardiovascular risk factors in the ARIC study. Am. J. Epidemiol. 134(3), 250-256 (1991).
102. O'Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 23(12), 1752-1760 (1992).
103. Romero JR, Beiser A, Seshadri S et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 40(5), 1590-1596 (2009).
104. Polak JF, Pencina MJ, O'Leary DH, D'Agostino RB. Common carotid artery intima-media thickness progression as a predictor of stroke in multi-ethnic study of atherosclerosis. Stroke 42(11), 3017-3021 (2011).
105. Sacco RL, Blanton SH, Slifer S et al. Heritability and linkage analysis for carotid intima-media thickness: the family study of stroke risk and carotid atherosclerosis. Stroke 40(7), 2307-2312 (2009).
106. Juo SH, Lin HF, Rundek T et al. Genetic and environmental contributions to carotid intimamedia thickness and obesity phenotypes in the Northern Manhattan Family Study. Stroke 35(10), 2243-2247 (2004). (Pubitemid 39311243)
107. Fox CS, Cupples LA, Chazaro I et al. Genomewide linkage analysis for internal carotid artery intimal medial thickness: evidence for linkage to chromosome 12. Am. J. Hum. Genet. 74(2), 253-261 (2004). (Pubitemid 38168613)
108. Wang D, Yang H, Quinones MJ et al. A genome-wide scan for carotid artery intima-media thickness: the Mexican-American Coronary Artery Disease family study. Stroke 36(3), 540-545 (2005). (Pubitemid 40344153)
109. Liao YC, Lin HF, Rundek T et al. Segmentspecific genetic effects on carotid intima-media thickness: the Northern Manhattan Study. Stroke 39(12), 3159-3165 (2008).
110. Rundek T, Elkind MS, Pittman J et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke 33(5), 1420-1423 (2002). (Pubitemid 34517070)
111. Lanktree MB, Hegele RA, Yusuf S, Anand SS. Multi-ethnic genetic association study of carotid intima-media thickness using a targeted cardiovascular SNP microarray. Stroke 40(10), 3173-3179 (2009).
112. Humphries SE, Morgan L. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol. 3(4), 227-235 (2004). (Pubitemid 38373661)
113. Manolio TA, Boerwinkle E, O'Donnell CJ, Wilson AF. Genetics of ultrasonographic carotid atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24(9), 1567-1577 (2004). (Pubitemid 39180878)
114. Bis JC, Kavousi M, Franceschini N et al. Meta-analysis of genome-wide association studies from the CHARGE consortium identifies common variants associated with carotid intima media thickness and plaque. Nat. Genet. 43(10), 940-947 (2011).
115. Dong C, Beecham A, Slifer S et al. Genomewide linkage and peakwide association analyses of carotid plaque in Caribbean Hispanics. Stroke 41, 2750-2756 (2010).
116. Pankow JS, Heiss G, Evans GW et al. Familial aggregation and genome-wide linkage analysis of carotid artery plaque: the NHLBI family heart study. Hum. Hered. 57(2), 80-89 (2004). (Pubitemid 38798150)
117. Moskau S, Golla A, Grothe C et al. Heritability of carotid artery atherosclerotic lesions: an ultrasound study in 154 families. Stroke 36(1), 5-8 (2005). (Pubitemid 40054167)
118. Bowden DW, Lehtinen AB, Ziegler JT et al. Genetic epidemiology of subclinical cardiovascular disease in the diabetes heart study. Ann. Hum. Genet. 72(5), 598-610 (2008).
119. Gardener H, Beecham A, Cabral D et al. Carotid plaque and candidate genes related to inflammation and endothelial function in Hispanics from Northern Manhattan. Stroke 42(4), 889-896 (2011).
120. Wang L, Yanuck D, Beecham A et al. A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque. Stroke 42(3), 588-592 (2011).
121. Dong C, Della-Morte D, Wang L et al. Association of the sirtuin and mitochondrial uncoupling protein genes with carotid plaque. PLoS ONE 6(11), e27157 (2011).
122. Lehtinen AB, Cox AJ, Ziegler JT et al. Genetic mapping of vascular calcified plaque loci on chromosome 16p in European Americans from the diabetes heart study. Ann. Hum. Genet. 75(2), 222-235 (2011).
123. Papaspyridonos M, Smith A, Burnand KG et al. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler. Thromb. Vasc. Biol. 26(8), 1837-1844 (2006). (Pubitemid 44305338)
124. Ansell J, Hirsh J, Hylek E et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl.), 160S-198S (2008). (Pubitemid 351892967)
125. Oake N, Jennings A, Forster AJ et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 179(3), 235-244 (2008).
126. Gage BF. Pharmacogenetics-based coumarin therapy. Hematology Am. Soc. Hematol. Educ. Program 467-473
127. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7(2), 97-104 (2005). (Pubitemid 40261834)
128. Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007). (Pubitemid 46421137)
129. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 13(5), 247-252 (2003). (Pubitemid 36583990)
130. Visser LE, van Vliet M, van Schaik RH et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 14(1), 27-33 (2004). (Pubitemid 38183959)
131. Rost S, Fregin A, Ivaskevicius V et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427(6974), 537-541 (2004). (Pubitemid 38209110)
132. Rieder MJ, Reiner AP, Gage BF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22), 2285-2293 (2005). (Pubitemid 40740552)
133. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 11(4), 493-496 (2010).
134. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
135. Epstein RS, Moyer TP, Aubert RE et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco- Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 55(25), 2804-2812 (2010).
136. Gong IY, Tirona RG, Schwarz UI et al. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118(11), 3163-3171 (2011).
137. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 11(3), 439-448 (2010).
138. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409(6817), 202-207 (2001). (Pubitemid 32144286)
139. Mega JL, Simon T, Collet JP et al. Reducedfunction CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
140. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 Focused Update of the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 117(2), 261-295 (2008).
141. Meschia JF, Worrall BB, Rich SS. Genetic susceptibility to ischemic stroke. Nat. Rev. Neurol. 7(7), 369-378 (2011).
142. Bhatt DL. Tailoring antiplatelet therapy based on pharmacogenomics: how well do the data fit? JAMA 302(8), 896-897 (2009).
143. Marin F, Gonzalez-Conejero R, Capranzano P et al. Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol. 54(12), 1041-1057 (2009).
144. Pare G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18), 1704-1714 (2010).
145. Simon T, Verstuyft C, Mary-Krause M et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4), 363-375 (2009).
146. Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2010).
147. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb. Haemost. 106(2), 191-202 (2011).
148. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
149. Zhou SF, Di YM, Chan E et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr. Drug Metab. 9(8), 738-784 (2008).
150. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl Acad. Sci. USA 97(7), 3473-3478 (2000). (Pubitemid 30183327)
151. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494-502 (2001). (Pubitemid 32758501)
152. Connolly SJ, Pogue J, Hart RG et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360(20), 2066-2078 (2009).
153. Bhatt D. CHARISMA genomics substudy: evaluation of the CYP2C19 polymorphism in a prospective, randomized, placebo-controlled trial of chronic clopidogrel use for primary and secondary prevention. Presented at: The Transcatheter Cardiovascular Therapeutics Conference. San Francisco, CA, USA, 21-26 September 2009.
154. Gurbel PA, Bliden KP, Antonino MJ et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J. Thromb. Haemost. 8(1), 43-53 (2010).
155. El Husseini N, Laskowitz DT. Clinical application of blood biomarkers in cerebrovascular disease. Expert Rev. Neurother. 10(2), 189-203 (2010).